The nation of Zimbabwe has turned down a significant US healthcare agreement valued at 367 million US dollars (272 million pounds) over five years due to Washington's insistence on sensitive biological samples.
This move came to light following a internal memorandum dated December was disclosed, revealing that Head of State Emmerson Mnangagwa felt the arrangement was "lopsided".
An official representative later explained that the United States was requesting biological samples for research and commercial gain but was unwilling to guarantee the resulting advantages from future treatments.
"We are forced to start the challenging and unfortunate task of winding down our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the United States had furnished over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has urged further negotiations to find a agreement agreeable to both sides so the country's vital HIV programme can proceed.
Wider Context
This rejection follows a comparable case in neighbouring Kenya, where a high court blocked a similar health funding agreement after legal challenges were filed about the security of citizens' medical information.
Since returning to the presidency recently, US President Donald Trump has reduced overseas assistance and shut down the US Agency for International Development (USAID).
USAID had managed aid for the US government, but Trump argued its spending was "inefficient" and his government was seeking direct bilateral agreements to boost transparency and accountability.
Based on statements, 16 nations in Africa have so far signed similar agreements, constituting more than $18.3bn in committed funds.
Details of the Rejected Agreement
The funds for Zimbabwe would have supported "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"It is our view this collaboration would have delivered extraordinary benefits for the people of Zimbabwe, especially the 1.2 million men, women and children presently receiving antiretroviral therapy through American-funded programmes," the Ambassador added.
However, official spokesman Nick Mangwana maintained the proposed deal was "asymmetrical".
"Our nation was requested to share its genetic material and health information for a long time, with no equivalent assurance of benefiting from any scientific breakthroughs – such as new medicines or tests – that could be developed from that shared data," Mangwana explained.
"Put simply, our nation would provide the raw materials for scientific discovery without any assurance that the end products would be accessible to our citizens if a new pandemic emerge."
Sovereignty and Global Health
Mangwana further pointed out that the US's withdrawal from the global health body and its pursuit of one-on-one health agreements were undermining systems previously set up via the international organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing system designed to deal with potential global health emergencies.
"This framework is intended to guarantee that when a country provides its data, the resulting advantages – such as vaccines and treatments – are shared equitably, not commercialised exclusively by those with the resources to develop them."
The government's concerns over the US deal "are not meant as hostility towards the US," he added.
"We welcome continued dialogue with our US partners on how subsequent co-operation could be designed in a way that respects the independence and interests of both nations."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it acknowledged the government's concerns, but suggested that negotiations need to persist considering much of the nation's HIV programmes were funded by foreign aid.
"Where specific concerns exist, such as those relating to data governance or agreement terms, these can often be addressed via detailed discussion and mutually agreed protections," the group commented.
This impasse emphasises the complex debate between receiving crucial foreign assistance and safeguarding a country's data in an ever more data-driven world.